5月7日,云顶新耀(01952)发布公告,宣布耐赋康®(NEFECON®)已获得中国国家药品监督管理局的完全批准,用于治疗具有疾病进展风险的原发性IgA肾病成人患者。这一批准取消了对蛋白尿水平的限制,使耐赋康®成为中国首个且唯一获得完全批准的IgA肾病对因治疗药物。此次批准基于NefIgArdIII期临床研究的完整数据,该研究显示耐赋康®能显著减少肾功能衰退,尤其在中国人群中,能延缓肾功能衰退达...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.